Abstract
Objective:
To investigate if phentermine treatment induces phentermine abuse, psychological dependence (addiction) or phentermine drug craving in overweight, obese and weight loss maintenance patients. To investigate whether amphetamine-like withdrawal occurs after abrupt cessation of long-term phentermine treatment.
Design:
Clinical intervention trial with interruption of phentermine treatment in long-term patients.
Subjects:
269 obese, overweight or formerly obese subjects (age: 20–88 years, BMI: 21–74 kg m−2) treated with phentermine long-term (LTP, N=117), 1.1–21.1 years, or short-term (ATP, N=152), 4–22 days, with phentermine doses of 18.75–112.5 (LTP) and 15–93.75 (ATP) mg per day.
Measurements:
Module K of the Mini International Neuropsychiatric Interview modified for phentermine (MINI-SUD), Severity of Dependence Scale (SDS), 45-item Cocaine Craving Questionnaire-NOW (CCQ-NOW) modified for phentermine (PCQ-NOW), and Amphetamine Withdrawal Questionnaire (AWQ) modified for phentermine (PWQ).
Results:
MINI-SUD interviews were negative for phentermine abuse or psychological dependence in all LTP patients. SDS examination scores were low for all LTP and ATP patients, indicating they were not psychologically dependent upon phentermine. PCQ-NOW scores were low for all LTP and ATP patients, indicating neither short-term nor long-term phentermine treatment had induced phentermine craving. Other than an increase in hunger or eating, amphetamine-like withdrawal symptoms did not occur upon abrupt phentermine cessation as measured by sequential PWQ scores.
Conclusions:
Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity. Phentermine treatment does not induce phentermine drug craving, a hallmark sign of addiction. Amphetamine-like withdrawal does not occur upon abrupt treatment cessation even at doses much higher than commonly recommended and after treatment durations of up to 21 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Samaranayake NR, Ong KL, Leung RY, Cheung BM . Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008. Ann Epidemiol 2012; 22: 349–353.
Colman E . Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005; 143: 380–385.
Glazer G . Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001; 161: 1814–1824.
Ioannides-Demos LL, Piccenna L, McNeil JJ . Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; 2011: 179674.
Kang JG, Park CY, Kang JH, Park YW, Park SW . Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab 2010; 12: 876–882.
Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR . Effects on weight reduction and safety of short-term phentermine administration in korean obese people. Yonsei Med J 2006; 47: 614–625.
Frank A . The long-term management of obesity with continuing pharmacotherapy. Obes Res 2004; 12: 1821–1827.
Hendricks EJ, Greenway FL, Westman EC, Gupta AK . Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 2011; 19: 2351–2360.
Rothman RB . Treatment of obesity with ‘combination’ pharmacotherapy. Am J Ther 2010; 17: 596–603.
Hendricks EJ, Rothman RB, Greenway FL . How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009; 17: 1730–1735.
Hendricks EJ, Greenway FL . A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther 2011; 18: 292–299.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl 20): 22–33 quiz 34-57.
Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607–614.
Tiffany ST, Singleton E, Haertzen CA, Henningfield JE . The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34: 19–28.
McGregor C Amphetamine withdrawal:nature, time course, and treatment. PhD Thesis. Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, 2005, 224pp.
Srisurapanont M, Jarusuraisin N, Jittiwutikan J . Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust N Z J Psychiatry 1999; 33: 89–93.
Heinz AJ, Epstein DH, Schroeder JR, Singleton EG, Heishman SJ, Preston KL . Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat 2006; 31: 355–364.
Bruno R, Matthews AJ, Topp L, Degenhardt L, Gomez R, Dunn M . Can the severity of dependence scale be usefully applied to ‘ecstasy’? Neuropsychobiology 2009; 60: 137–147.
Topp L, Mattick RP . Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997; 92: 839–845.
Kaye S, Darke S . Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction 2002; 97: 727–731.
Martin G, Copeland J, Gates P, Gilmour S . The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off. Drug Alcohol Depend 2006; 83: 90–93.
Tiffany ST, Wray JM . The clinical significance of drug craving. Ann N Y Acad Sci 2012; 1248: 1–17.
Newton TF, De La Garza R 2nd, Kalechstein AD, Tziortzis D, Jacobsen CA . Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. Am J Addict 2009; 18: 294–300.
McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM . The nature, time course and severity of methamphetamine withdrawal. Addiction 2005; 100: 1320–1329.
van Rossum JM, Simons F . Locomotor activity and anorexogenic action. Psychopharmacologia 1969; 14: 248–254.
Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R . Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 959–964.
Kish SJ . Pharmacologic mechanisms of crystal meth. CMAJ 2008; 178: 1679–1682.
Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 2010; 105: 1809–1818.
Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H . Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 1996; 14: 233–241.
Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ . Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008; 95: 140–146.
Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A et al. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. J Clin Psychopharmacol 2012; 32: 492–502.
Couper FJ, Pemberton M, Jarvis A, Hughes M, Logan BK . Prevalence of drug use in commercial tractor-trailer drivers. J Forensic Sci 2002; 47: 562–567.
Lee S, Kim J, In S, Choi H, Chung H, Chung KH . Detection of phentermine in hair samples from drug suspects. Forensic Sci Int 2011; 207: e5–e7.
Jain NC, Budd RD, Sneath TC . Frequency of use or abuse of amphetamine-related drugs. Am J Drug Alcohol Abuse 1979; 6: 53–57.
Greene WM, Sylvester M, Abraham J . Addiction liability of pharmacotherapeutic interventions in obesity. Curr Pharm Des 2011; 17: 1188–1192.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edn American Psychiatric Association: Washington, DC, USA, 2000.
O'Brien CP, Volkow N, Li TK . What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry 2006; 163: 764–765.
Kampman KM, Volpicelli JR, McGinnis DE, Alterman AI, Weinrieb RM, D'Angelo L et al. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav 1998; 23: 449–461.
Shoptaw SJ, Kao U, Heinzerling K, Ling W . Treatment for amphetamine withdrawal. Cochrane Database Syst Rev 2009; CD003021 doi: 10.1002/14651858.
Ahmadi J, Kampman K, Dackis C . Outcome predictors in cocaine dependence treatment trials. Am J Addict 2006; 15: 434–439.
Ahmadi J, Kampman KM, Oslin DM, Pettinati HM, Dackis C, Sparkman T . Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. Am J Addict 2009; 18: 81–86.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Hendricks has received honoraria from Akramax Pharmaceuticals, Eurodrug Laboratories, Citius Pharmaceuticals and Vivus pharmaceuticals. Dr Greenway has received honoraria from Baronova, Basic Research, Citius, Diabetic Living, Eisai, GNC, Jenny Craig, Lithera, Merck, Naturalpha, Nume Health, Orexigen, Plensat, Takeda, Thetis, Unigene and Zafgen. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hendricks, E., Srisurapanont, M., Schmidt, S. et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes 38, 292–298 (2014). https://doi.org/10.1038/ijo.2013.74
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2013.74
Keywords
- phentermine
- weight loss
- addiction
- abuse
- dependence
- withdrawal
This article is cited by
-
Current pharmacotherapy for obesity
Nature Reviews Endocrinology (2018)
-
Effect of phentermine on weight reduction in a pediatric weight management clinic
International Journal of Obesity (2017)
-
How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals
Obesity Surgery (2015)
-
New Pharmacological Treatments for the Management of Obesity
Current Gastroenterology Reports (2014)